Did you know that there are over 1031 viruses on this earth…? That’s ten nonillion?!
This is Virus of the Week:
The Science Social has made it their mission to introduce a virus each week to help raise general understanding of virology. We don’t think we will get through all the viruses through this series, just a select few.
Here are some of the things that you will learn about each virus that we chose to present to you each week:
“Did you know…?”
And of course, a reference list from peer reviewed articles so you can be assured, we are not making it up!
But wait… I don’t know what any of that means…
Taxonomy is a tool used by scientists to classify all living things. Think of it as a bit like a really big, detailed family tree which shows you how closely related each living thing is. This was developed by a Swedish botanist named Carolus Linnaeus back in the 18th century. In short, all living things are grouped into 7 Kingdoms of life; e.g. Animalia, Plantae, Fungi, Chromista, Protozoa, Archaea and Bacteria. Each Kingdom of life are then split further into Phylum > Class > Phylum > Order > Family > Genus > Species.
The scientific classification of a human is:
Domain: Eukaryota Kingdom: Animalia Phylum: Chordata Class: Mammalia Order: Primates Family: Hominidae Genus: Homo Species:sapiens
I’m sure you are all familiar with Homo sapiens, well this is how we, as humans, fit into the taxonomy hierarchy.
Live Science give a good overview of taxonomy here!
The Taxonomy of Viruses though?!
The International Committee on Taxonomy of Viruses (ICTV) are responsible for developing, refining and maintaining a universal virus taxonomy. You can find more out about them here.
This one literally means, where did the name come from.
We will be discussing what hosts the virus of the week can replicate in. We will be looking at viruses where the humans are the main host, but also others too.
This is a fancy scientific way of saying, which cells in the body (or organism) the virus is “attracted” too. For example, this virus infects mainly these cells.
How is the virus transmitted?! Through the air? A vector (for example a mosquito or a tick…?), contaminated food or water?
What does the infection of this particularly look like in the form of disease?
Did you know?:
We thought we would throw in a fun fact… just to attempt at making this interesting.
Remember we have a virology section on our blog which you can find here!
We hope you enjoy virus of the week – we are really excited to share this with you!
One medicine promotes collaboration between doctors, vets, scientists and other medical professionals so veterinary and human medicine can evolve and improve so both benefit from equal medical progress (1).
One health focuses specifically on how the health of people is closely connected to the health of animals and our shared environment (2).
History of One Health, One Medicine
The concept of one medicine and one health has been around for a LONG time…
It was first referred to by Rudolf Virchow, regarded as the father of modern pathology (3) whose discoveries on Trichinella spiralis in pork led to valuable public health measures.
Even today Vets are heavily involved in food production to stop contamination or disease entering the human food chain. Virchow was one of the first to coin the term “zoonosis” and proclaimed that there should be no dividing line between human and animal medicine (4,5).
Sir William Osler, regarded as the father of modern medicine,was another key figure in promoting one medicine, as he taught medical students at McGill College and veterinary students at the Montreal Veterinary College in the 1870s.
Demonstrating how one subject area could co exist and benefit the other. Osler published on the relation of animals to man and promoted comparative pathology and the One Medicine Concept (4,5).
In the 20th century, Calvin Schwabe coined the concept of “one medicine” in a modern age, recognising that there is very little difference between human and veterinary medicine and both disciplines can contribute to the development of each other (4).
Zoonosis = Disease that can transmit between humans and animals.
What are the applications of one health, one medicine?
If you have seen the bionic vet then you already know a fantastic example of one medicine. Professor Noel Fitzpatrick routinely uses human medical principles for orthopaedic surgery to conduct the incredible surgeries he does on the nation’s beloved pets!
Further more general applications include:
Why should we care?
It is more ethical – both animals and humans are benefitting from this kind of research.
There is potential for faster medical progress.
This type of research could result in more animal and humans lives saved.
Better quality of life for humans and animals is achieved.
Ultimately, this type of research has an even bigger impact.
Cardiff, R.D., Ward, J.M. and Barthold, S.W., 2008. ‘One medicine—one pathology’: are veterinary and human pathology prepared?. Laboratory investigation, 88(1), pp.18-26.
Zinsstag, J., Schelling, E., Waltner-Toews, D. and Tanner, M., 2011. From “one medicine” to “one health” and systemic approaches to health and well-being. Preventive veterinary medicine, 101(3-4), pp.148-156.
Kahn, L.H., Kaplan, B., Monath, T.P. and Steele, J.H., 2008. Teaching “one medicine, one health”. The American journal of medicine, 121(3), p.169.
COVID-19 fatality may be associated with damage caused by our immune system as opposed to direct damage from the virus. Dexamethasone, a drug that has recently proved to reduce fatality in severely ill COVID-19 patients, suggests that inflammation plays a direct role in patient outcomes.
Is the inflammation caused be the virus itself, or the body’s immune system? Currently, this is unknown.
For a quick recap on the immune system: visit our infographic here.
The ICECAP consortia have released a preprint in MedRxiv that may hold the answer to this question. Tissues from 12 individuals who have died from COVID-19 in hospital were analysed by a team of pathologists, clinicians and virologists to determine where the virus was found and whether this corresponded to where inflammation was found.
Who are ICECAP?
ICECAP: Inflammation in COVID-19-Exploration of Critical Aspects of Pathogenesis.
“ICECAP was established as a rapid response to the COVID-19 pandemic. We collect and analyse tissue samples to understand COVID-19 and other fatal diseases, contributing to finding tests and treatments for these conditions.”
Inflammation: a local immune response to cellular injury.
Post-mortem: the study of the deceased.
Immune system: a system of the body that fights off infection and disease, including white blood cells, antibodies and the organs that produce these cells.
Macrophage: a specialised immune cell involved in the innate immune response.
Plasma cell: an immune cell that produces antibodies that make up the adaptive immune response.
Pulmonary: relating to the lungs.
The Coronavirus was found in multiple organs within patients who died from COVID-19.
Most commonly in the lungs but also in other parts of the body, such as the heart, muscle and the gastrointestinal tract. In some cases, virus was detected in the liver, kidney and other organs.
Inflammation was not observed in non-pulmonary organs
Interestingly, virus that was detected outside of the lung, was usually not associated with local inflammation, despite frequent detection of viral RNA and protein. This was the case for tissues such as the intestine, liver and kidney.
Inflammation was identified in lung tissue
Lung damage consisted of significant injury to the alveoli (the part of the lung involved in uptake of oxygen), the identification of blood clots and inflammation of pulmonary blood vessels. Interestingly again, there was not a consistent association between the presence of viral RNA and either the presence or nature of the inflammatory response within the lung.
Abnormalities of the blood and the immune system
Abnormalities were found in the blood and immune system; two key cell types are discussed:
Macrophages – an immune cell that is involved in sensing and responding to pathogens and tissue repair.
Plasma cells – cells involved in producing antibodies.
Abnormal macrophages and an increased number of abnormal plasma cells were identified in the organs of the immune system. Within damaged lung tissues, the researchers identified that macrophages and macrophage-like cells were in high numbers.
The consequence of these abnormalities is currently unknown; however, this finding provides a direction for COVID-19 researchers and future studies.
The take home message from this research is that different tissues appear to have a different tolerance to the virus. Inflammation and damage to organs are likely to be extensively mediated by the body’s own immune system, and drives outcome from disease.
A note on preprint and peer review:
This research has not gone through the peer review process yet – visit our posts on peer review here.
Interested in communicating your research to a lay audience? Get in touch at firstname.lastname@example.org
Thank you to Dr Chris Lucas, an ICECAP investigator and co-author of the original article for permission to write this blog, and for the valuable comments.
Glaucoma is the leading cause of irreversible blindness worldwide (1). As patients age, cells in the eye gradually deteriorate, causing patients to eventually go completely blind. Scientists at Liverpool University believe that by replacing these non-working cells with working ones, vision loss may be prevented!
What’s happening in glaucoma?
Our eyes are filled with fluid, known as aqueous humour, that is constantly filtered by a tissue called the trabecular meshwork (2). In glaucoma, the cells that make up this tissue decrease in numbers and those remaining don’t function as they should do (3). This prevents the fluid from moving through the meshwork as it becomes stiffer and blocked by debris, causing pressure in the eye to increase (4). This pressure damages axons of the optic nerves preventing signals that contain visual information being sent to the brain (5).
Treating Glaucoma Today
Currently glaucoma treatments involve laser treatments or surgery to create channels for the fluid to drain out of the eye and reduce pressure, which unfortunately aren’t always effective (6). If the lost cells of the trabecular meshwork in glaucoma patients could be replaced with healthy cells, then the trabecular meshwork may be able to function normally and regulate pressure in the eye.
Hiding in plain sight?
The problem lies in how to develop these working cells and get them to where they need to be? Well, recent scientific discoveries find that these cells may be “hiding in plain sight”.
By changing the environment in the trabecular meshwork, we may be able to make use of cells already present in the eye, that have a unique ability to develop into specialised cell types, stem cells (7). In the right conditions, these stem cells can be encouraged to grow into healthy and functioning cells that could aid in aqueous humour outflow. What scientists need to know, is what changes are needed to make this happen…and that’s what is currently being investigated at Liverpool University!
Think of it like gardening. Flower seeds buried deep in dry and old soil, won’t blossom anytime soon. But if you replace the soil with fresh, nutritious compost and plenty of water you’ll have a flourishing garden. By finding the right compost and supplying water, scientists can replace non-working cells with healthy ones, without having to transplant new cells into patients.
Liu, B. et al. (2018) ‘Aging and ocular tissue stiffness in glaucoma’, Survey of Ophthalmology. Elsevier USA, pp. 56–74. doi: 10.1016/j.survophthal.2017.06.007.
Tamm, E. R. (2009) ‘The trabecular meshwork outflow pathways: Structural and functional aspects’, Experimental Eye Research. Academic Press, pp. 648–655. doi: 10.1016/j.exer.2009.02.007.
Liton, P. B. et al. (2005) ‘Cellular senescence in the glaucomatous outflow pathway’, Experimental Gerontology. NIH Public Access, 40(8–9), pp. 745–748. doi: 10.1016/j.exger.2005.06.005.
dysregulation in glaucoma’, Experimental Eye Research. Academic Press, pp. 112–125. doi: 10.1016/j.exer.2014.07.014.
Quigley, H. A. (2011) ‘Glaucoma’, The Lancet, 377(9774), pp. 1367–1377. doi: 10.1016/S0140-6736(10)61423-7.
Weinreb, R. N., Aung, T. and Medeiros, F. A. (2014) ‘The pathophysiology and treatment of glaucoma: A review’, JAMA – Journal of the American Medical Association. American Medical Association, pp. 1901–1911. doi: 10.1001/jama.2014.3192.
Yun, H. et al. (2016) ‘Stem cells in the trabecular meshwork for regulating intraocular pressure’, Journal of Ocular Pharmacology and Therapeutics. Mary Ann Liebert Inc., 32(5), pp. 253–260. doi: 10.1089/jop.2016.0005.
Everyday thousands of healthy kidney cells are shed into our urine. Under the right conditions, these cells, known as urine-derived renal epithelial cells, or hURECs for short, can be collected as a liquid biopsy, and used to study a wide range of rare genetic kidney diseases without a traditional painful invasive biopsy.
What do the Kidneys do?
The kidneys are bean shaped organs found towards the back of the upper abdomen involved in the ultrafiltration of our blood. Our kidneys are vital in maintaining appropriate water levels, and produce waste products like urea which is excreted in urine.
Who is affected by kidney disease?
In the UK alone, one in ten people have Chronic Kidney Disease (CKD); this equates to around 3 million patients in total (1). There are a number of reasons for the onset of kidney disease, including poor control of blood sugar levels in diabetes, high blood pressure or inherited causes.
What diseases can we study using these cells?
In our Newcastle University Renal Genetics group, we predominantly study a group of diseases known as ciliopathies, which occur due to cilia defects. Found on the surface of almost all cells, cilia are finger-like protrusions acting like radio antennae feeding information back to the control centre of the cell, known as the nucleus. Ciliopathies can affect a number of organ systems, including the eyes, brain, liver and kidneys. Examples of ciliopathies affecting the kidneys include Joubert Syndrome, Oral-facial-digital Syndrome, Nephronophthisis and Autosomal Dominant Polycystic Kidney Disease, all of which we can study using hURECs.
How have these cells been used?
For many years, the Newcastle University Renal Genetics group we have been using hURECs to further understand how and why kidney disease develops in ciliopathies like Joubert Syndrome (3; 4) and Nephronophthisis (5). These hURECs allow us to investigate both the phenotype (characteristics that we can see) and the genotype (the genetic blueprint including genes and DNA) which are involved in renal ciliopathies, giving much desired answers to patients and their families.
Remarkably, hURECs have been used in our hands to generate 3D cell models known as organoids which can be considered as ‘kidneys in a dish’. These renal organoids, known as tubuloids (6) or nephrospheres (7), have allowed for more complex kidney disease modelling.
What does this mean for patients?
One of the main benefits of using hURECs is that we can gain a kidney organ specific snapshot of how the renal cilia are affected, which can sometimes be missed using other cell types like fibroblasts, which are derived from skin biopsies. Urine sample collection in order to grow hURECs is also quick, easy and most importantly pain free, meaning multiple samples can be taken. Exciting opportunities in the development of patient-specific hUREC generated disease models highlight why urine samples, a waste product, may hold the key to developing our understanding of kidney diseases.
1. Kidney Research UK. Annual Reports and Accounts. Kidney Research UK. [Online] 2020. [Cited: 26 06 2020.] https://kidneyresearchuk.org/about-us/annual-reports/.
2. Ciliopathies: an expanding disease spectrum. Waters, A M and Beales, P L. 7, 2011, Pediatric Nephrology, Vol. 26, pp. 1039-1056.
3. A human patient-derived cellular model of Joubert syndrome reveals ciliary defects which can be rescued with targeted therapies. Srivastava, S, et al. 23, 2017, Human Molecular Genetics, Vol. 26, pp. 4657-4667.
4. Targeted exon skipping of a CEP290 mutation rescues Joubert syndrome phenotypes in vitro and in a murine model. Ramsbottom, S A, et al. 49, 2018, PNAS, Vol. 115, pp. 12489-12494.
5. Human urine-derived renal epithelial cells provide insights into kidney-specific alternate splicing variants. Molinari, E, et al. 2018, European Journal of Human Genetics, Vol. 26, pp. 1791-1796.
6. Tubuloids derived from human adult kidney and urine for personalized disease modeling. Schutgens, F, et al. 2019, Nature Biotechnology, Vol. 37, pp. 303-313.
7. Urinary nephrospheres indicate recovery from acute kidney injury in renal allograft recipients – a piolet study. Knafl, D, et al. 251, 2019, BMC Nephrology, Vol. 20.
Caenorhabditis elegans is a type of tiny soil-dwelling worm, found to accept certain human genes into their own genome . These ‘humanised’ worms are a very useful tool to study human disease, with researchers at the University of Liverpool now using them to study human epilepsy and discover new anti-epileptic drugs  .
What is epilepsy?
Epilepsy is one of the most common conditions affecting the brain, shaping the lives of an estimated 50 million people worldwide . In the UK alone, there are an estimated 600,000 epilepsy patients, which is almost 1 in every 100 people, with 87 people diagnosed every day . There are a lot of different causes of epilepsy, and it can affect people of all ages .
Those with epilepsy suffer from recurrent seizures, which is caused by sudden bursts of electrical activity within the brain. The most well-known seizure type affects movement, causing muscle jerking, twitching, and/or weakness. Lesser known seizures affect the person’s awareness to their surroundings and can cause changes in sensation or emotion .
Currently, there are over 20 anti-epileptic drugs available with many different drug targets . These drugs try to stop the sudden uncontrolled bursts of electrical activity within the brain. However, these anti-epileptic drugs do not work for one third of patients, named ‘refractory epilepsy’, with the reason for this not fully understood . Therefore, new drugs are desperately needed for those patients with refractory epilepsy.
Why worms for drug development?
Making new drugs is controversial as testing on mammals, like mice and primates, has many ethical and financial issues. As these worms are invertebrates, less complex animals, they do not require extensive ethical training for use . Also, these worms have a short reproduction time (~3 days) and lifespan (~3 weeks) and do not need expensive equipment take care of them, making them a much cheaper alternative . Therefore, it is beneficial to test new drugs on less complex animals first, and then move onto more complex animals later in the drug development process. However, it is hard to justify using tiny soil-dwelling worms to test drugs for humans when we are so different .
Humanising the worm
To tackle this, researchers led by Professor Alan Morgan at the University of Liverpool have created humanised worms to study severe forms of epilepsy, such as Ohtahara syndrome . This was achieved, in part, using the highly specialised gene editing process CRIPSR-Cas9 and which is used to insert, delete, or substitute target genes, to fix or introduce gene mutations .
GABA is a neurotransmitter (a biological chemical) which can prevent sudden electrical activity in the human brain. Studies by multiple different research teams have found GABA mutations (more specifically GABAA receptors) in patients with a spectrum of epileptic encephalopathies, such as Lennox-Gastaut syndrome and West syndrome .
In this project we aim to introduce mutated human GABAA receptor genes found in epilepsy patients into worms. We will then induce seizures in the worms and test a range of new anti-seizure drugs to see which compounds are most effective. Therefore, we will be able to assess the effect the new anti-seizure drugs may have in humans with the same genetic mutations.
Using these humanised worms as a first step in drug development is beneficial as it gives researchers the opportunity to fast-track the selection process, whittling down large numbers of drug candidates to a select few in a short space of time .
1. Zhu, B., et al., Functional analysis of epilepsy-associated variants in STXBP1/Munc18-1 using humanized Caenorhabditis elegans. Epilepsia, 2020. 61(4): p. 810-821.
2. Wong, S.Q., et al., A Caenorhabditis elegans assay of seizure-like activity optimised for identifying antiepileptic drugs and their mechanisms of action. J Neurosci Methods, 2018. 309: p. 132-142.
3. Organization, W.H., Epilepsy: a public health imperative. 2019: World Health Organization,.
7. Loscher, W., et al., New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov, 2013. 12(10): p. 757-76.
8. Kwan, P. and M.J. Brodie, Early identification of refractory epilepsy. N Engl J Med, 2000. 342(5): p. 314-9.
9. Cunliffe, V.T., et al., Epilepsy research methods update: Understanding the causes of epileptic seizures and identifying new treatments using non-mammalian model organisms. Seizure, 2015. 24: p. 44-51.
10. Chen, X., et al., Using C. elegans to discover therapeutic compounds for ageing-associated neurodegenerative diseases. Chem Cent J, 2015. 9: p. 65.
11. Zhang, F., Y. Wen, and X. Guo, CRISPR/Cas9 for genome editing: progress, implications and challenges. Hum Mol Genet, 2014. 23(R1): p. R40-6.
12. O’Reilly, L.P., et al., C. elegans in high-throughput drug discovery. Adv Drug Deliv Rev, 2014. 69-70: p. 247-53.
13. Hernandez, C.C. and R.L. Macdonald, A structural look at GABAA receptor mutations linked to epilepsy syndromes. Brain Res, 2019. 1714: p. 234-247.
The global COVID-19 pandemic picture is still unclear as the novel coronavirus outbreak shifts constantly around the world. While the number of cases rise critically in South America’s first wave, the UK and European countries have begun to lift their lockdown measures amidst this COVID-19 pandemic. At the same time, South Korea and China, where coronavirus cases seemed to have disappeared, have seen a second wave of infections. However, a common question emerges among this COVID-19 rollercoaster: Will we have a vaccine soon?
A matter of time
Timing is crucial in vaccine research. More than five months have passed since the genetic sequence of SARS- CoV-2, the virus that causes COVID-19, which was published on 11th January 2020. This discovery sparked an unprecedented global research effort to develop a vaccine against this disease1, involving next-generation technology platforms and novel approaches with a hope to speed up this process. However, vaccine development involves a multi-stage process of research and testing, which typically takes more than ten years to be completed2 (Fig. 1). Therefore, we must remain cautious in light of a new vaccine.
What is the current picture?
A recent overview of the global landscape of COVID-19 vaccines by the World Health Organisation (WHO) included more than 140 vaccine candidates from different research groups and developers around the world3. From those, 129 candidate vaccines are under preclinical evaluation, which means a preliminary laboratory exploration but not yet in human trials. On the other hand, 13 candidate vaccines have entered the clinical evaluation stage, which is a three-phase process involving human subjects (Fig. 2).
OK, but can we speed up this process?
In terms of vaccine research time we are progressing at super-fast speed in this scenario. Just consider that the first set of COVID-19 cases, a new type of viral pneumonia, were reported to WHO on 4th January 2020 (Fig.3). Two months later, the first COVID-19 vaccine entered first-in-human trials within record breaking time on 16th March 2020. Scientists and international organizations around the world are still racing to produce and deliver a safe and effective vaccine within an 18-month period1-3.
So, do we have a vaccine yet?
From the array of advanced COVID-19 candidates under clinical development, only one promising study has started their phase 3 trial in Brazil4 (Fig. 4). This a non-replicative viral vector vaccine developed by the University of Oxford and the British-Swedish company AstraZeneca5. As we previously described, this candidate works as an inactive vaccine by using a different non-live virus to deliver coronavirus genes into our cells. In other terms, it can´t reproduce itself but it can still provoke an immune response.
Currently, this vaccine is also moving to Phase II/III in England and will hopefully deliver positive results by next year. A different approach has been employed by The Murdoch Children’s Research Institute in Australia. The experimental coronavirus vaccine, which is currently in phase 3 trial, utilises the Bacillus Calmette-Guerin vaccine6. The BCG vaccine is made from a weakened strain of tuberculosis bacteria and been widely used since the 1920s to fight TB7.
Researchers expect to observe partial protection against SARS-COV-2 as observed for other diseases7,8. Only data and results will decide if the remaining vaccine candidates could progress to phase 3 human trials and if this global effort could be translated into a successful vaccine by early 2021.
Usher AD. COVID-19 vaccines for all?. Lancet. 2020;395(10240):1822-1823. doi:10.1016/S0140-6736(20)31354-4
Thanh Le T, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305-306. doi:10.1038/d41573-020-00073-5
On May 10th, 2020 the UK Government announced that Secondary Schools, Sixth Forms and Further Education Colleges could provide some face-to-face support for year 10 and year 12 students after June 1st 2020. This was subsequently deferred to start on 15th June (1). Students in these year groups have national exams in Summer 2021. This means this time in year 10 and year 12 is critical as the bulk of the curriculum is delivered.
To reduce the spread of COVID-19 in schools on the return of students, the government has advised the regular cleaning of frequently touched surfaces, changing classroom layouts to reduce student contact and to stagger timetables (2). However, what are the students’ views on returning to school?
It was important to me to get this question answered, so I designed a study in aim to voice the views of students.
Why is this research important?
It is not apparent that the Government has engaged with the school students affected most by this decision. Students have not been given a platform to raise their concerns about returning to education. Their views have not been heard.
This motivated me to conduct a prospective study to collate the views of young people and publicise their concerns. It is important to involve young people in decisions that affect their situation so that they engage with the policy (3). Year 10 and year 12 students are also of an age where their opinions should be taken into account.
Aims of the research project:
This study was conducted to explore the opinions of year 10s and 12s concerning returning to partial school after the first wave of the covid-19 outbreak in June 2020. The aim was to provide a voice to young people on returning to partial schooling in June 2020.
Students were invited to express:
Their preferences on returning to school
Their views about safety with respect to government guidance on return to school
How they feel COVID-19 will impact on their future
How COVID-19 has impacted on their education
This study will inform members of the public and policy makers about the opinions of year 10 and 12 students returning to school in the UK at the end of the first wave of the SARS-CoV-2 outbreak.
How the research was conducted:
The aims of this study were addressed with qualitative research using a prospective survey conducted from the 20th to 27th May 2020. Participants were year 10 (age 14 to 15 years old) and year 12 (age 16 to 17 years old) school students in the United Kingdom.
A 12-question survey was compiled on Google Forms™ with 9 close-ended questions and 3 open-ended questions. The survey was distributed to the students via two online Facebook™ forums specific to their year groups: The A level Forum (6,500 members) and a GCSE forum (36,000 members). The survey was accessible on multiple platforms (computers and smartphones) and multiple web browsers.
The 3 open ended questions were subject to Braun and Clarke themed analysis. Thematic analysis is a method for identifying and interpreting patterns of meaning across qualitative data. This meant recurring themes in the written data could be addressed and the reasons behind students’ answers could be found without influence. Braun and Clarke analysis provides a qualitative six phased method of thematic analysis. Firstly, I familiarised myself with the qualitative data and noted general ideas. NVIVO (v12) software was used to group the qualitative data into codes (similar patterns in the data). Themes were then put together by grouping the codes. I then reviewed and defined each theme in relation to the research measures.
There was a rapid uptake from students with 1534 responses in 7 days.
Year 10 and 12 school students are evenly divided in opinion about whether they should return to school on 15th June. This uncertainty appears based on the majority of students having concerns about schools’ ability to comply with government guidance, particularly around social distancing and the risk of transmission. Some students recognised a need to return to education despite this perceived risk. This uncertainty could be addressed by better engagement from policy makers with school students. School students expressed desire that their students’ concerns are addressed by the Government and better explanation of the reasoning behind returning certain students to school at this time whilst other members of the community continue to isolate.
Policy makers should standardise remote learning. This will ensure all students receive some educational support during pandemics, ensuring the educational divide caused by a lockdown is minimized.
1. Actions for schools during the coronavirus outbreak [Internet]. GOV.UK. 2020 [cited 2020 Jun 9]. Available from: https://www.gov.uk/government/publications/covid-19-school-closures/guidance-for-schools-about-temporarily-closing
2. Coronavirus (COVID-19): implementing protective measures in education and childcare settings [Internet]. GOV.UK. 2020 [cited 2020 Jun 9]. Available from: https://www.gov.uk/government/publications/coronavirus-covid-19-implementing-protective-measures-in-education-and-childcare-settings/coronavirus-covid-19-implementing-protective-measures-in-education-and-childcare-settings
3. Mitchell C. “The Girl Should Just Clean Up the Mess”: On Studying Audiences in Understanding the Meaningful Engagement of Young People in Policy-Making. Int J Qual Methods [Internet]. 2017 Dec 1 [cited 2020 Jun 6];16(1):1609406917703501. Available from: https://doi.org/10.1177/1609406917703501
A second simultaneous Ebola outbreak has been confirmed in the Democratic Republic of Congo (DRC), (World Health Organization, 2020). This marks the 11th Ebola outbreak in central Africa which comes at a time when the continent also battles the COVID-19 pandemic.
First discovered in 1976, ebola viruses have since re-emerged across the African continent. The virus reached international attention during the longest and most extensive Ebola outbreak in West Africa between 2013 – 2015.
Historical Ebola outbreaks have fatality rates as high as 88%, almost 9 out of 10 people would die as a result of infection. The West Africa outbreak, however, saw a drastic reduction in fatality rate, to around 40%. The reduction in fatality rate was likely a result of the increased basic support, advanced and more appropriate care for those infected and earlier case detection, allowing for better management of both patients and outbreak spread (Baseler et al., 2017).
The most recent outbreak is in Mbandaka in the Équateur region, 600 miles from the ongoing Kivu Ebola epidemic in the North Kivu and Ituri provinces. The cases in Mbandaka are thought to be separate from the Kivu Ebola epidemic and instead the result of a new ‘spillover’ event from an animal reservoir to humans.
As of the 10th of June, a total of 12 cases have been reported; 9 confirmed cases, 3 suspected cases and 6 deaths, (Bujakera, Holland and Heavens, 2020)*. Positive samples were confirmed via testing at the Institut National de Recherche Biomédicale (INRB) – the countries national medical research organisation.
Although case number is relatively small at present, this is likely to rise as contacts are traced and the incubation period of 2-21 days elapses. Whilst the outbreak has presented at an already challenging time, scientists and doctors are on the ground with capacity to trace and diagnose. This service was expanded and refined in 2018 in response to previous outbreaks (World Health Organization, 2020).
The Kivu Ebola epidemic began in August 2018, over 3,400 people have been infected and sadly 2,200 lives lost despite the implementation of aggressive control measures. A number of factors have hindered this operation including; stigmatization, civil unrest and logistical issues.
Community level prevention and outbreak measures are dependent on the public trusting local authorities, however 31.9% of 961 individuals surveyed in North Kivu trusted that local authorities were acting in their best interests. The same survey reported 25.5 % of those surveyed believed the outbreak was a hoax, (Vinck et al., 2019). Complicating this were populist politicians publishing their own doubts on the outbreak validity to gain support in the 2018 elections. The country had not yet had a peaceful transition of power since decolonialisation in 1960, (Moran, 2018).
However, deployment of an experimental vaccine, coupled with rapid diagnostics helped to halt the outbreak. Following emergency use in 2016, the Ervebo vaccine was finally approved for use in 2019, after clinical trial demonstrated safety and efficacy; 97.5% efficacy in preventing Ebola infection compared to no vaccination, (Regules et al., 2015; World Health Organization, 2019).
Although an effective vaccination is now available, this is by no means the end of the problem. Availability, difficulties in contact tracing and public perception are all challenges that must be addressed to manage the outbreak during an already arduous time.
It is hoped that authorities and individuals alike can action their learnings from previous outbreaks, to bring this new outbreak to a swift end.
The DRC is currently contending with outbreaks of cholera, SARS-CoV-2, measles and two separate Ebola clusters. This serves as a stark reminder that whilst the world fights against the SARS-CoV-2 pandemic, Ebola outbreaks will stop for no country and no person.
Viruses emerge, or spillover often in nature, ebola virus is an example of this. Check out our blog on viral emergence here, or our post about bats and viruses.
*Please note that this article is not by a scientific body and reports figures from a WHO press conference which could not be confirmed on WHO.int.
Written by Charlotte Rigby
Baseler, L. et al. (2017) ‘The Pathogenesis of Ebola Virus Disease’, Annual Review of Pathology: Mechanisms of Disease, 12(1), pp. 387–418. doi: 10.1146/annurev-pathol-052016-100506.
Bujakera, S., Holland, H. H. and Heavens, A. (2020) Up to 12 infected in Congo’s new Ebola outbreak: WHO, Reuters.
Moran, B. (2018) ‘Fighting Ebola in conflict in the DR Congo’, The Lancet. Elsevier, 392(10155), pp. 1295–1296. doi: 10.1016/S0140-6736(18)32512-1.
Regules, J. A. et al. (2015) ‘A Recombinant Vesicular Stomatitis Virus Ebola Vaccine’, New England Journal of Medicine. Massachusetts Medical Society, 376(4), pp. 330–341. doi: 10.1056/NEJMoa1414216.
Vinck, P. et al. (2019) ‘Institutional trust and misinformation in the response to the 2018–19 Ebola outbreak in North Kivu, DR Congo: a population-based survey’, The Lancet Infectious Diseases, 19(5), pp. 529–536. doi: https://doi.org/10.1016/S1473-3099(19)30063-5.
World Health Organization (2019) Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic response. doi: 10.1016/j.surfcoat.2019.125084.
World Health Organization (2020) New Ebola outbreak detected in northwest Democratic Republic of the Congo; WHO surge team supporting the response. Available at: https://www.who.int/news-room/detail/01-06-2020-new-ebola-outbreak-detected-in-northwest-democratic-republic-of-the-congo-who-surge-team-supporting-the-response (Accessed: 2 June 2020).
Written by Rebekah Penrice-Randal and Lucia Livoti
Features of 20,133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study 1 was published in The British Medical Journal (BMJ) this week. This report defines clinical characteristics of patients in hospital in the UK, using the ISARIC WHO Clinical Characterisation Protocol. We have written a brief summary to define what this means, discuss the report itself and highlight the key findings to aid public understanding.
You can follow the study on twitter for more updates: @CCPUKstudy
What is the ISARIC WHO Clinical Characterisation Protocol?
A research protocol is the set of documents that includes the instructions for conducting a study, the participant information sheets and consent forms. A clinical research protocol has to be approved by an independent Research Ethics Committee to ensure patient safety and dignity, and in the UK, by the Health Research Authority to ensure that health care resources are used appropriately.
In other words, the study was set up in advance of an outbreak to ask the “who, what and why” of a new disease. Who is affected means, age, sex, ethnicity and underlying medical problems. What means, what does the disease cause any of: breathing problems, diarrhoea, vomiting, sepsis or bleeding.
The ISARIC WHO CCP allows for the collecting of clinical data and biological samples, and their analysis and processing to be done in a globally-harmonised manner. This protocol has been curated by multidisciplinary experts across the world 2, and employed in response to outbreaks such as:
Middle Eastern Respiratory Virus Syndrome coronavirus (MERS-CoV) in 2012,
Influenza in 2013,
Ebola virus in 2014,
Monkeypox and MERS-CoV in 2018,
Tick-borne encephalitis virus (TBEV) in 2019 and
SARS-CoV-2 in 2020.
The ISARIC WHO CCP has been central to the swift and cohesive research response to COVID-19. As a free, readily available resource it has been instrumental in the standardised collection of samples and data for the COVID-19 outbreak. This in turn has allowed clinical investigation to progress as quickly as possible. Global generic documents can be accessed here. Countries are also encouraged to develop “localised” instructions and seek local research permissions. The documents pertaining to UK protocols are available here.
Cohort: a cohort of patients are a group of individuals affected by a common factor, such as a disease, treatments or environmental factors.
Cohort study: cohort studies are central to the study of epidemiology and are often used in the fields of medicine, nursing, psychology and social sciences.
Comorbidity: presence of one or more medical conditions in addition to the condition being studied.
Epidemiology: the study and analysis of factors contributing to disease and health outcomes. In this case it may refer to the frequency and pattern of COVID-19 infection, risk factors, super-spreader events and study of specific populations.
Median: the median is defined as the ‘middle’ value of a data set, such that other values are equally likely to be above or below.
Risk factor: a factor that increases an individual’s risk or susceptibility to a disease.
Aim of the study:
To rapidly understand the clinical characteristics of people severely affected by COVID-19. Severely affected, meaning those who need hospital care.
Why is this work important?
This work is essential to appreciate the clinical features of patients that present with COVID-19 and identify risk factors associated with poor outcome. It is only through the understanding of such aspects that public policy can be informed, particularly around shielding of vulnerable groups and planning of resources such as oxygen and ventilator provision.
Who took part?
20,133 hospital in-patients with COVID-19 from 208 acute care hospitals across the UK were enrolled into the study. Clinical data was collected from patients admitted to hospital between 6th February and 19th April 2020. Patient outcomes are described as known on 3rd May 2020, as people admitted on the 19th April need at least 14 days to complete their admission or “declare the nature of their illness”.
The ISARIC WHO CCP-UK is a large ongoing study of patients hospitalised with COVID-19. This study found that the mortality rate was high in those admitted to hospital. Certain risk factors were associated with higher mortality rate such as; increasing age, male sex, and chronic comorbidity, including obesity. This report provides the first clinical insight of hospital patients with COVID-19 in the UK. The data gathered throughout this study will assist decision-making in the management of COVID-19, from patient to nation.
This report acknowledges the 2648 frontline NHS clinical and research staff, volunteer medical students and many researchers, who have worked tirelessly to make this study happen. Thank you to all involved and congratulations from The Science Social.
A note on ‘open access’
Open access journal articles are available to everyone and are not behind a pay wall. This article is freely available to all, if you would like to read the original article click here.
1 Docherty, A. B. et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ369, m1985, doi:10.1136/bmj.m1985 (2020).
2 Dunning, J. W. et al. Open source clinical science for emerging infections. The Lancet Infectious Diseases14, 8-9, doi:10.1016/S1473-3099(13)70327-X (2014).
Thank you to Professor Calum Semple (@tweediechap), an ISARIC investigator and co-author of the original article for permission to write this blog, and for the valuable comments.
All feedback and comments are welcome, get in touch: